CliffBio
biologic

Wezlana

ustekinumab-auub

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameWezlana
Active ingredientustekinumab-auub
Strength45MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2023
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Wezlana patent cliff — loss of exclusivity — | CliffBio